Clinical trial design and endpoints in kidney transplantation
Transplant International
Patient-Reported Outcomes as Endpoints in Clinical Trials of Kidney Transplantation Interventions
Allison Tong , Rainer Oberbauer , Maria Irene Bellini , Klemens Budde , Fergus J. Caskey, Fabienne Dobbels , Liset Pengel , Lionel Rostaing , Stefan Schneeberger and Maarten Naesens
Published on 20 May 2022
Transpl Int doi: 10.3389/ti.2022.10135
Proposed Definitions of T Cell-Mediated Rejection and Tubulointerstitial Inflammation as Clinical Trial Endpoints in Kidney Transplantation
Daniel Seron , Marion Rabant, Jan Ulrich Becker , Candice Roufosse , Maria Irene Bellini , Georg A. Böhmig , Klemens Budde , Fritz Diekmann, Denis Glotz, Luuk Hilbrands , Alexandre Loupy, Rainer Oberbauer , Liset Pengel , Stefan Schneeberger and Maarten NaesensPublished on 20 May 2022
Transpl Int doi: 10.3389/ti.2022.10135
Surrogate Endpoints for Late Kidney Transplantation Failure
Maarten Naesens , Klemens Budde , Luuk Hilbrands , Rainer Oberbauer , Maria Irene Bellini , Denis Glotz, Josep Grinyó , Uwe Heemann , Ina Jochmans , Liset Pengel , Marlies Reinders, Stefan Schneeberger and Alexandre Loupy
Published on 20 May 2022
Transpl Int doi: 10.3389/ti.2022.10136
Rationale for Surrogate Endpoints and Conditional Marketing Authorization of New Therapies for Kidney Transplantation
Maarten Naesens , Alexandre Loupy, Luuk Hilbrands , Rainer Oberbauer , Maria Irene Bellini , Denis Glotz, Josep Grinyó , Uwe Heemann , Ina Jochmans , Liset Pengel , Marlies Reinders, Stefan Schneeberger and Klemens Budde
Published on 20 May 2022
Transpl Int doi: 10.3389/ti.2022.10137
Alloimmune Risk Stratification for Kidney Transplant Rejection
Oriol Bestard, Olivier Thaunat , Maria Irene Bellini , Georg A. Böhmig , Klemens Budde , Frans Claas , Lionel Couzi , Lucrezia Furian , Uwe Heemann , Nizam Mamode, Rainer Oberbauer , Liset Pengel , Stefan Schneeberger and Maarten Naesens
Published on 20 May 2022
Transpl Int doi: 10.3389/ti.2022.10138
Allograft Function as Endpoint for Clinical Trials in Kidney Transplantation
Luuk Hilbrands , Klemens Budde , Maria Irene Bellini , Fritz Diekmann, Lucrezia Furian , Josep Grinyó , Uwe Heemann, Dennis A. Hesselink , Alexandre Loupy, Rainer Oberbauer , Liset Pengel , Marlies Reinders, Stefan Schneeberger and Maarten Naesens
Published on 20 May 2022
Transpl Int doi: 10.3389/ti.2022.10139
Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation
Candice Roufosse , Jan Ulrich Becker , Marion Rabant, Daniel Seron , Maria Irene Bellini , Georg A. Böhmig , Klemens Budde , Fritz Diekmann, Denis Glotz, Luuk Hilbrands , Alexandre Loupy, Rainer Oberbauer , Liset Pengel , Stefan Schneeberger and Maarten Naesens
Published on 20 May 2022
Transpl Int doi: 10.3389/ti.2022.10140
Evolution of the Definition of Rejection in Kidney Transplantation and Its Use as an Endpoint in Clinical Trials
Jan Ulrich Becker , Daniel Seron , Marion Rabant, Candice Roufosse and Maarten Naesens
Published on 20 May 2022
Transpl Int doi: 10.3389/ti.2022.10141
Redefining Risk Stratification and Endpoints for Clinical Trials in Kidney Transplantation: Rationale and Methodology of Proposals Submitted to the European Medicines Agency by the European Society for Organ Transplantation
Maarten Naesens , Stefan Schneeberger , the ESOT Working Group , Maarten Naesens, Jan Ulrich Becker, Maria Irene Bellini, Oriol Bestard, Georg A. Böhmig, Klemens Budde, Fergus Caskey, Frans Claas, Lionel Couzi, Fritz Diekmann, Fabienne Dobbels, Lucrezia Furian, Denis Glotz, Josep Grinyó, Uwe Heemann, Dennis Hesselink, Luuk Hilbrands, Ina Jochmans, Alexandre Loupy, Nizam Mamode, Rainer Oberbauer, Liset Pengel, Marion Rabant, Marlies Reinders, Lionel Rostaing, Candice Roufosse, Stefan Schneeberger, Daniel Seron, Olivier Thaunat and Allison Tong
Published on 20 May 2022
Transpl Int doi: 10.3389/ti.2021.10142